Table 1B.
Group | Animal ID | Neutralizing antibody titers |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
8 days after challenge |
24 days after challenge |
||||||||||
AHSV 1 | AHSV 4 | AHSV 5 | AHSV 6 | AHSV 8 | AHSV 1 | AHSV 4 | AHSV 5 | AHSV 6 | AHSV 8 | ||
A ECRA.A4 |
A1 | nd | 64 | nd | nd | nd | nd | 32 | nd | nd | nd |
A2 | nd | 32 | nd | nd | nd | nd | 16 | nd | nd | nd | |
A3 | nd | ≥256 | nd | nd | nd | nd | 64 | nd | nd | nd | |
A4 | nd | 64 | nd | nd | nd | nd | ≥256 | nd | nd | nd | |
B ECRA .A1/4/6/8 |
B1 | 16 | 32 | – | 4 | 8 | 8 | 16 | – | 4 | 8 |
B2 | – | 64 | – | – | 8 | 4 | 32 | – | – | 4 | |
B3 | 4 | ≥256 | 4 | 16 | 32 | 4 | 128 | – | 16 | 32 | |
B4 | – | ≥256 | 4 | – | 8 | – | 32 | – | – | – | |
C Control |
C1 | – | 4 | – | – | – | nd | nd | nd | nd | nd |
C2 | – | – | – | – | – | nd | nd | nd | nd | nd |